12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Patiromer: Completed Phase III enrollment

Relypsa completed enrollment of 240 patients in a 2-part, international Phase III trial of twice-daily patiromer. The single-blind first part will evaluate patiromer in all patients. The second part...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >